| Q30635519 | A hybrid feature subset selection algorithm for analysis of high correlation proteomic data |
| Q33302448 | A robust biomarker discovery pipeline for high-performance mass spectrometry data |
| Q33259996 | A simple method to combine multiple molecular biomarkers for dichotomous diagnostic classification |
| Q36232263 | Anti-tumor antibodies in ovarian cancer. |
| Q44087175 | Bias as a threat to the validity of cancer molecular-marker research |
| Q33420422 | Bias, randomization, and ovarian proteomic data: a reply to "producers and consumers". |
| Q37346072 | Biomarker discovery in ovarian cancer. |
| Q99634733 | Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer |
| Q28550057 | Changes in the Proteome of Langat-Infected Ixodes scapularis ISE6 Cells: Metabolic Pathways Associated with Flavivirus Infection |
| Q36389455 | Classification algorithms for phenotype prediction in genomics and proteomics |
| Q35850684 | Clinical proteomics: Applications for prostate cancer biomarker discovery and detection |
| Q35053674 | Clinical proteomics: present and future prospects. |
| Q33448583 | Comparison of computational algorithms for the classification of liver cancer using SELDI mass spectrometry: a case study |
| Q33221189 | Correcting common errors in identifying cancer-specific serum peptide signatures |
| Q31083527 | Detection of bladder cancer using proteomic profiling of urine sediments |
| Q33288265 | Detection of venous thromboembolism by proteomic serum biomarkers |
| Q30982896 | Importance of communication between producers and consumers of publicly available experimental data |
| Q52973479 | Lessons from controversy: ovarian cancer screening and serum proteomics. |
| Q33224210 | Mass spectrometry in diagnostic oncoproteomics |
| Q35767356 | Methodologies and experimental platforms for generating and analysing microarray and mass spectrometry-based omics data to support P4 medicine |
| Q36677487 | Multiple biomarker panels for early detection of ovarian cancer |
| Q35580496 | Opportunities and challenges in omics |
| Q33449299 | Ovarian cancer classification based on mass spectrometry analysis of sera |
| Q30985505 | Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data |
| Q33448554 | Parametric power spectral density analysis of noise from instrumentation in MALDI TOF mass spectrometry |
| Q36501871 | Phyloproteomics: what phylogenetic analysis reveals about serum proteomics |
| Q33270113 | Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer |
| Q31153300 | Proteomics and the analysis of proteomic data: an overview of current protein-profiling technologies |
| Q51963671 | Qualified predictions for microarray and proteomics pattern diagnostics with confidence machines. |
| Q79852778 | Rules of evidence for cancer molecular-marker discovery and validation |
| Q59093391 | Running before we can walk? |
| Q35611709 | Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease |
| Q57556802 | Signal in Noise: Evaluating Reported Reproducibility of Serum Proteomic Tests for Ovarian Cancer |
| Q33289727 | Technology insight: the application of proteomics in gastrointestinal disease |
| Q47587382 | The potential of serum proteomics for detection of cancer: promise or only hope? |
| Q33508672 | The role of proteomics in the diagnosis and treatment of ovarian cancer |
| Q33420432 | Understanding the characteristics of mass spectrometry data through the use of simulation. |